ArticleCurrent treatment options in neurology2015
What is New in the Management of Epilepsy in Gliomas?
Article in Current treatment options in neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Correlation Between Tumor Molecular Markers and Perioperative Epilepsy in Patients With Glioma: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2021Pooled it
- Trial
- From bedside to bench: New insights in epilepsy-associated tumors based on recent classification updates and animal models on brain tumor networks.Molecular oncology · 2024Review
- Surgical treatment of long-term epilepsy-associated tumors guided by stereoelectroencephalography.European journal of medical research · 2024Article
- Chinese guideline on the application of anti-seizure medications in the perioperative period of supratentorial craniocerebral surgery.Therapeutic advances in neurological disorders · 2022Review
- Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review.Neuro-oncology practice · 2021Review
- The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide.Journal of neuro-oncology · 2021Article
- Comparison of In Vivo and Ex Vivo Magnetic Resonance Imaging in a Rat Model for Glioblastoma-Associated Epilepsy.Diagnostics (Basel, Switzerland) · 2021Article
- Development of a Rat Model for Glioma-Related Epilepsy.International journal of molecular sciences · 2020Article
- Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better.Neuro-oncology practice · 2020Article
- Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study.Journal of neurology · 2018Observational
- Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study.Journal of neuro-oncology · 2018Observational
- Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study.Oncology letters · 2017Article
- Mutant IDH1 and seizures in patients with glioma.Neurology · 2017Article
- Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.Neuro-oncology · 2017Review
- Does the choice of antiepileptic drug affect survival in glioblastoma patients?Journal of neuro-oncology · 2016Article
- Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.Neuro-oncology · 2016Review
- Article
- Seizure outcomes as an understudied metric in glioma clinical trials: A review of the ClinicalTrials.gov database.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementSeizures represent a common symptom in low- and high-grade gliomas. Tumor location and histology influence the risk for epilepsy. Some molecular factors (BRAF V 600E mutations in glioneuronal tumors and IDH1/2 mutations in diffuse grade II and III gliomas) are molecular factors that are relevant for diagnosis and prognosis and have been associated with the risk of epilepsy as well. Glutamate plays a central role in epileptogenicity and growth of glial and glioneuronal tumors, based on the release of glutamate from tumor cells that enhances excitotoxicity, and a downregulation of the inhibitory GABAergic pathways. Several potential targets for therapy have been identified, and m-TOR inhibitors have already shown activity. Gross total resection is the strongest predictor of seizure freedom in addition to clinical factors, such as preoperative seizure duration, type, and control with antiepileptic drugs (AEDs). Radiotherapy and chemotherapy with alkylating agents (procarbazine, CCNU, vincristine, temozolomide) are effective in reducing the frequency of seizures in patients with pharmacoresistant epilepsy. Newer AEDs (in particular levetiracetam and lacosamide) seem to be better tolerated than the old AEDs (phenobarbital, phenytoin, carbamazepine), but randomized clinical trials are needed to prove their superiority in terms of efficacy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.